B-cell lymphoma 2 (BCL-2) family proteins (BCL-2 family)

The apoptosis regulatory balance, often referred to as the "apoptotic rheostat," is the functional equilibrium between pro-apoptotic and anti-apoptotic members of the B-cell lymphoma 2 (BCL-2) protein family (Korsmeyer et al., 1993, PubMed: 8248125). This balance is a critical determinant of cell fate, where anti-apoptotic proteins like BCL-2, BCL-XL, and MCL-1 inhibit the pro-apoptotic activity of BAX and BAK to prevent mitochondrial outer membrane permeabilization (Czabotar et al., 2014, Nature Reviews Molecular Cell Biology). In many cancers, this balance is pathologically shifted toward survival, allowing malignant cells to evade programmed cell death and resist therapy. Drugs known as BH3 mimetics, such as Venetoclax, are designed to restore this balance by selectively binding and inhibiting anti-apoptotic proteins, thereby triggering apoptosis in cancer cells (Youle & Strasser, 2008, Nature Reviews Molecular Cell Biology). While "apoptosis regulatory balance" describes a vital biological process and therapeutic goal, it is not a single molecular target but rather a complex interaction network primarily governed by the BCL-2 family (PubChem CID: 49846579).

Other names

Apoptosis regulatory balanceApoptotic rheostatBcl-2 family balanceProgrammed cell death regulationBcl-2 rheostat

Inhibition of anti-apoptotic BCL-2 family members (BCL-2, BCL-XL, MCL-1) to restore the apoptotic rheostat and promote BAX/BAK-mediated mitochondrial outer membrane permeabilization and subsequent cell death (Czabotar et al., 2014, Nature Reviews Molecular Cell Biology).